One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...
Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...
Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...
The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?
The deal concerns the connectivity between Glooko's self-titled mobile app and Dexcom's continuous glucose monitoring (CGM) devices. Currently, Dexcom device users upload CGM data to the Glooko app ...
Our editors tested two popular glucose monitors to determine which is the best for improving diet, sleep and exercise habits.
A manufacturing problem in millions of Abbott glucose sensors for diabetes patients has been tied to at least seven deaths ...
New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics ...
BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.
Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.
Type 2 diabetes is not reversible, but it can go into remission, meaning your blood sugar levels return to normal without medication for at least three months. Some people can achieve this by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results